Cybin is trading at $11.25, up 5.24%; broader biotech strength is the likeliest available context, not a confirmed cause. - No clear company-specific announcement explaining the October 20 move was identified. An investor presentation is scheduled for October 21, not today. - Biotech rose 2.10% during the regular session, amid sector-wide M&A activity and positive clinical-trial sentiment. - Current volume and unusual trading activity were not available.